Michigan Rep. Jack Bergman Says Psychedelic Treatment Research Has Reached a New Moment
Rep. Jack Bergman, a Michigan Republican and one of Congress’s leading voices on psychedelic medicine, says the window for action has opened wider. Speaking at a Capitol Hill event on psychedelic treatments and America’s mental health crisis, Bergman said federal leaders should move faster on research, especially for veterans and people with severe mental health conditions.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Point | What It Means |
|---|---|
| Bergman sees urgency | He believes federal support has created a rare opening for psychedelic research. |
| Veterans remain central | PTSD, depression, and suicide risk continue to drive congressional interest. |
| Research is the priority | Bergman said he cares less about specific compounds and more about outcomes. |
| Federal policy may shift | Recent executive branch support could push agencies to move faster. |
| Access still depends on evidence | These therapies need strong data, clear rules, and trained clinical teams. |
New:Â Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
A Push From Congress
Bergman helped launch the Congressional Psychedelics Advancing Therapies Caucus, known as the PATH Caucus. The group has worked to bring psychedelic medicine into mainstream federal policy discussions.
That matters because psychedelic treatment is no longer just a cultural debate. It is now a regulatory, medical, and public health question.
That means clinical trials. It means safety monitoring. It means therapist training, medical oversight, and clear guidance from federal agencies.
Why Veterans Are Driving the Conversation
Veterans have become one of the most visible groups in this debate. Many live with PTSD, depression, traumatic brain injury, chronic pain, or substance use disorders. Standard treatments help some patients. They leave others searching for relief.
Bergman, a retired Marine Corps lieutenant general, has framed psychedelic research through that lens. He has argued that the country owes veterans serious investigation into treatments that could help when existing options fail.
That does not mean every psychedelic compound will work. It does not mean every patient will be a candidate. It does mean Congress is paying closer attention to the gap between need and available care.
The FDA Question
The next stage will likely depend on the FDA, the Department of Veterans Affairs, and clinical trial sponsors. Psychedelic medicine cannot advance on public interest alone.
Regulators will need to evaluate safety, durability, dosing, psychological support, and adverse events. They will also need to decide how these therapies fit into medical practice.
That is where the field often gets complicated. Psychedelic treatment is not simply a pill handed across a counter. Many models involve preparation, monitored dosing, and integration afterward.
For clinics, researchers, and patients, that structure matters as much as the compound itself.
What Comes Next
Bergman’s comments reflect a broader shift in Washington. Psychedelic medicine is moving from the margins into serious policy rooms.
Still, the field has to avoid overpromising. The strongest case for access will come from careful science, not hype.
For patients, the takeaway is cautious optimism. More federal attention could mean more research, more funding, and a clearer path for future therapies. But access will still take time.
The question now is not whether psychedelic medicine deserves study. That argument has largely changed. The question is how quickly the country can build the evidence, safeguards, and clinical systems needed to do it well.
